Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | GNAI3 | P08754 | 4/20 | 0.46 |
| ▸ | GNAI1 | P63096 | 4/20 | 0.46 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 4/20 | 0.44 |
| ▸ | CES1 | P23141 | 4/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7116803 | 0.98 | L3MBTL1 (0.50) | L3MBTL1MEN1KMT2ATDP1SMN1; SMN2 | |
| SCHEMBL28182514 | 0.98 | L3MBTL1 (0.50) | L3MBTL1MEN1KMT2ATDP1SMN1; SMN2 | |
| SCHEMBL7064500 | 0.98 | L3MBTL1 (0.50) | L3MBTL1MEN1KMT2ATDP1SMN1; SMN2 | |
| SCHEMBL672952 | 0.94 | MEN1 (0.51) | L3MBTL1MEN1KMT2ATDP1SMN1; SMN2 | |
| SCHEMBL673525 | 0.91 | SMN1; SMN2 (0.54) | L3MBTL1MEN1KMT2ATDP1SMN1; SMN2 | |
| SCHEMBL1782094 | 0.89 | SMN1; SMN2 (0.52) | L3MBTL1MEN1KMT2ATDP1SMN1; SMN2 | |
| SCHEMBL12591056 | 0.85 | SMN1; SMN2 (0.46) | L3MBTL1MEN1KMT2ATDP1SMN1; SMN2 | |
| SCHEMBL673711 | 0.85 | — | — | |
| SCHEMBL22540869 | 0.83 | SMN1; SMN2 (0.44) | L3MBTL1MEN1KMT2ATDP1SMN1; SMN2 | |
| SCHEMBL28786674 | 0.83 | SMN1; SMN2 (0.47) | L3MBTL1MEN1KMT2ATDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035209-A1 | Hydroxy Substituted 1H-Imidazopyridines and Methods | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20100152230-A1 | HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS | PFIZER INC. | 2010-06-17 | — | — | US | disclosed |
| CN-101253173-A | Hydroxy substituted 1H-imidazopyridines and methods | PFIZER (US) | 2008-08-27 | — | — | CN | disclosed |
| EP-1924581-A1 | HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS | Pfizer, Inc. (US) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007028129-A1 | HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS | PFIZER INC. (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152230-A1 | HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS | IL4, IL2, IL4I1 | L3MBTL1 4218/4885MEN1 3944/4885KMT2A 3563/4885 |
| US-20120035209-A1 | Hydroxy Substituted 1H-Imidazopyridines and Methods | IL2, IL4, IL4I1 | L3MBTL1 4200/4885MEN1 3860/4885KMT2A 3668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.